First-of-its-kind vaccine protects children from deadly intestinal infections

"In children below the age of five, whose immune systems are still developing, the infections can lead to malnourishment; they cause up to 42,000 deaths annually. Soon there may be a vaccine to protect against these infections. In the Lancet Infectious Diseases last month, scientists shared the results of the first study to evaluate the safety and efficacy of an ETEC-controlling vaccine in a large pediatric population in Gambia."

"ETEC bacteria have adhesin proteins that enable them to attach themselves to the intestinal mucosa. The bacteria then release toxins, which lead to watery diarrhea and abdominal cramping. In low-income countries, a lack of access to sanitation and clean drinking water increases the risk of E. coli infections, resulting in more childhood fatalities and higher health care costs."

"An approved oral cholera vaccine called Dukoral provides partial protection against some forms of ETEC diarrhea, but at present, there is no approved E. coli vaccine available for protection against any type of E. coli infections in humans. ETVAX is the first to show significant protection against E. coli infections in people."

Enterotoxigenic Escherichia coli (ETEC) causes travelers' diarrhea and childhood diarrhea in low-income regions, resulting in approximately 42,000 annual deaths in children under five. ETEC bacteria use adhesin proteins to attach to intestinal mucosa and release toxins causing watery diarrhea and abdominal cramping. A new vaccine called ETVAX has completed its first large-scale pediatric safety and efficacy study in Gambia, showing immunity against the pathogen without adverse side effects. Currently, only Dukoral, an oral cholera vaccine, provides partial ETEC protection. ETVAX represents the first vaccine demonstrating significant protection against E. coli infections in humans, addressing a critical gap in disease prevention for vulnerable populations in areas lacking adequate sanitation and clean water access.

Read at www.scientificamerican.com